Elliott Sigal, M.D., Ph.D.

Elliott Sigal, M.D., Ph.D.

DirectoratVir Biotechnology· In proxies 2023–2025

Elliott Sigal, M.D., Ph.D. sits on 7 public boards.

Boards1

  • Vir BiotechnologyDirector · 3 yr on the boardIndependentCompensation, Science and Technology (Chair)—Paid as an executive

Board seats come from each company's latest proxy statement.

Experience

  1. Vir BiotechnologyPublic company · 3 yr
    • Director2023 – Present · 3 yrStock in role -52%
  2. Tessera TherapeuticsPublic company · 5 yr
    • Director2021 – Present · 5 yrNo stock prices for these years
  3. Affinia Therapeutics Inc.Public company · 6 yr
    • Director2020 – Present · 6 yrNo stock prices for these years
  4. Surface Oncology, Inc.Public company · 8 yr
    • Director2018 – Present · 8 yrNo stock prices for these years
  5. Adaptimmune TherapeuticsPublic company · 12 yr
    • Director2014 – Present · 12 yrNo stock prices for these years
  6. Mead Johnson Nutrition CompanyPublic company
    • Director? – PresentNo stock prices for these years
  7. Spark Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?